Sildenafil AUC, or area under the plasma concentration-time curve, is a pharmacokinetic metric used to summarize systemic drug exposure across time. Instead of describing the concentration at one moment, AUC integrates the concentration-time profile over a defined interval and therefore reflects the accumulated systemic exposure represented by the curve.
AUC answers a different question from Cmax or Tmax. Cmax describes the highest observed concentration, Tmax identifies when that peak occurs, and AUC captures exposure across the entire measured interval. Two concentration-time profiles can therefore have similar peaks but different AUC values, or similar AUC values despite different peak shapes.
This page focuses specifically on AUC as a sildenafil pharmacokinetic metric: how it is estimated, how AUC0-t and AUC0-∞ differ, why bioavailability and clearance influence it, and how labeling data illustrate changes in sildenafil exposure. The broader concept of exposure and its multiple determinants belongs on the sildenafil exposure page.
AUC represents the area beneath the sildenafil plasma concentration-time curve. Conceptually, it combines concentration and time into a single measure, so it summarizes the amount of systemic exposure represented across the interval being analyzed rather than describing one isolated concentration measurement.
Because AUC combines concentration and time, its units reflect both dimensions. For example, when plasma concentration is expressed in ng/mL and time in hours, AUC may be expressed as ng·h/mL. The exact unit depends on the concentration and time units used in the pharmacokinetic analysis.
Within the broader sildenafil pharmacokinetic framework, AUC is one of the principal measures of systemic exposure. It is especially useful when comparing exposure between doses, populations, formulations or conditions that alter how much sildenafil reaches or remains in circulation.
| Metric | Primary Meaning | Main Dimension |
|---|---|---|
| AUC | Integrated plasma exposure across time | Concentration × time |
| Cmax | Highest observed plasma concentration | Concentration |
| Tmax | Time of the observed concentration peak | Time |
A sildenafil concentration-time curve plots plasma concentration on the vertical axis and time after administration on the horizontal axis. AUC is the geometric area beneath that curve over a defined time interval, so every portion of the profile contributes to the final exposure estimate.
The rising absorption phase contributes area while concentrations increase, the peak region contributes exposure around Cmax, and the declining phase continues adding area even after the maximum concentration has passed. This is why AUC cannot be inferred from Cmax alone.
The shape of the curve and its total area are related but not identical concepts. Two curves can enclose a similar area while differing substantially in their peak height or timing. The sildenafil concentration-time guide focuses on interpretation of the full curve, while this page isolates the quantitative meaning of its area.
| Curve Region | Contribution to AUC |
|---|---|
| Early rising phase | Contributes exposure while concentrations increase. |
| Peak region | Contributes exposure around the highest measured concentrations. |
| Post-peak decline | Continues contributing exposure as concentrations fall. |
| Terminal phase | Can contribute extrapolated exposure when AUC is estimated beyond the final measured sample. |
AUC is derived from serial plasma concentration measurements collected at multiple time points after sildenafil administration. Because plasma concentration is sampled at discrete intervals rather than measured continuously, the area between those observations has to be estimated mathematically.
A common pharmacokinetic approach is the trapezoidal method. The area between two adjacent concentration measurements is approximated from their concentrations and the elapsed time between them, and the individual areas are then added to estimate exposure over the full sampling period.
Sampling design matters. Measurements need to characterize the rising phase, the region around Cmax and the declining phase sufficiently well for the estimated curve to represent the actual profile. Sparse sampling near the peak or inadequate terminal sampling can affect the resulting AUC estimate even when the analytical concentration measurements themselves are accurate.
| Measurement Step | Purpose |
|---|---|
| Serial plasma sampling | Provides concentration values at defined times. |
| Curve construction | Places measured concentrations in temporal sequence. |
| Area estimation | Estimates exposure between adjacent sampling points. |
| Area summation | Produces the AUC for the selected interval. |
AUC can be reported over different time intervals. AUC0-t generally describes exposure from administration through the final defined or quantifiable sampling time, meaning that most or all of this value comes directly from observed concentration measurements.
AUC0-∞ extends the estimate beyond the last measurable sample. The observed AUC is combined with an estimate of the remaining terminal area, commonly derived from the last measurable concentration and the terminal elimination rate. The result represents estimated exposure from administration toward infinite time.
These values are related but not interchangeable. If terminal sampling is inadequate, the extrapolated portion of AUC0-∞ becomes less certain. For that reason, interpreting total AUC involves considering not only the final number but also how much exposure was directly observed and how reliably the terminal decline was characterized.
| AUC Form | What It Represents |
|---|---|
| AUC0–t | Exposure from administration through the last defined or quantifiable sampling time. |
| AUC0–∞ | Observed exposure plus estimated terminal exposure beyond the final sample. |
| Partial AUC | Exposure measured over a specified subsection of the concentration-time profile. |
AUC and Cmax are both derived from the sildenafil concentration-time profile, but they answer different pharmacokinetic questions. Cmax identifies the highest observed concentration, while AUC integrates concentrations across time and therefore represents the extent of systemic exposure over the selected interval.
Two sildenafil profiles can have similar Cmax values but different AUC values if concentrations decline at different rates after the peak. Conversely, two profiles can generate similar total AUC while reaching different peak concentrations because one profile may be higher and narrower while another is lower and more prolonged.
This distinction is important when interpreting conditions that change sildenafil pharmacokinetics. A factor can affect peak concentration more strongly than total exposure or can substantially change AUC through slower clearance without producing the same proportional change in Cmax. Peak concentration magnitude is treated separately on the sildenafil Cmax page.
| Feature | AUC | Cmax |
|---|---|---|
| Primary question | How much systemic exposure occurs across time? | What is the highest observed concentration? |
| Uses multiple time points? | Yes | Peak value only |
| Captures peak magnitude? | Indirectly as part of total area | Directly |
| Represents total exposure? | Yes, over the defined interval | No |
Tmax is a timing parameter, while AUC is an exposure parameter. Tmax identifies the sampling time at which the observed maximum concentration occurs, whereas AUC integrates concentration across the complete interval being analyzed.
A change in absorption rate can move Tmax earlier or later without producing a corresponding proportional change in AUC. The early curve may shift in time while the accumulated area across the entire profile remains comparatively similar.
This distinction helps prevent peak timing from being mistaken for overall drug exposure. Peak timing is examined on the sildenafil Tmax page, where the relationship between absorption timing and the observed maximum concentration is treated separately.
Systemic bioavailability influences AUC because only sildenafil that reaches systemic circulation unchanged can contribute directly to the parent-drug plasma concentration curve. Sildenafil labeling reports a mean absolute oral bioavailability of approximately 41%, with a reported range of 25% to 63%.
AUC is commonly used when evaluating bioavailability because it summarizes systemic concentration across time. Under otherwise comparable conditions, greater systemic availability can produce greater AUC, but the relationship is not determined by bioavailability alone because clearance also influences how long sildenafil remains in circulation.
This is why AUC and bioavailability should not be treated as synonyms. AUC is the measured exposure outcome, whereas bioavailability describes systemic input relative to the administered dose. The sildenafil bioavailability page focuses specifically on the fraction reaching systemic circulation.
| Concept | Primary Meaning | Relationship to AUC |
|---|---|---|
| Bioavailability | Fraction reaching systemic circulation unchanged | Influences the amount of sildenafil available to generate systemic exposure. |
| AUC | Integrated plasma exposure across time | Observed exposure metric. |
| Clearance | Efficiency of systemic drug removal | Influences how long circulating exposure persists. |
AUC depends not only on how much sildenafil reaches systemic circulation but also on how efficiently it is removed. Under approximately linear pharmacokinetic conditions, the relationship can be summarized conceptually as systemic AUC increasing with bioavailable dose and decreasing as clearance increases.
Sildenafil labeling provides direct examples of this relationship. In volunteers with severe renal impairment, reduced sildenafil clearance was associated with approximately a doubling of AUC and Cmax. In volunteers with mild-to-moderate hepatic impairment, reduced clearance was associated with an approximately 85% increase in AUC and a 47% increase in Cmax.
These findings show why AUC is not simply an absorption measurement. Exposure can increase because systemic input changes, because elimination slows, or because both processes change. The elimination side of this relationship is examined in depth on the sildenafil clearance page.
| PK Change | Potential Relationship to AUC |
|---|---|
| Greater systemic input | Can increase AUC. |
| Lower systemic input | Can decrease AUC. |
| Slower clearance | Can increase AUC by prolonging circulating exposure. |
| Faster clearance | Can decrease AUC by removing drug more rapidly. |
Sildenafil prescribing information describes its pharmacokinetics as dose-proportional over the recommended dose range. In that setting, increasing administered dose is associated with a broadly corresponding increase in systemic exposure, including AUC.
Dose proportionality does not mean that AUC is a dosing instruction or that clinical effect rises in the same proportion. It is a pharmacokinetic observation about how systemic exposure scales with dose under the conditions in which proportionality has been established.
The relationship also should not automatically be extrapolated outside a studied range or into conditions that materially change absorption or clearance. The relationship between administered dose and exposure is treated specifically on the sildenafil dose proportionality page.
| Observation | Interpretive Question |
|---|---|
| AUC rises proportionally with dose | Is exposure approximately dose-proportional over the studied range? |
| AUC rises more than proportionally | Could a PK process be changing with increasing dose? |
| AUC rises less than proportionally | Could systemic input or elimination behave nonlinearly? |
Sildenafil AUC can vary between individuals and study conditions because integrated exposure reflects systemic input, metabolism and clearance together. Age, organ function, metabolic enzyme activity and interacting drugs can therefore alter AUC even when the administered sildenafil dose is unchanged.
Labeling provides several examples of substantial exposure changes. Healthy volunteers aged 65 years or older had approximately 84% higher total sildenafil AUC than younger volunteers. Severe renal impairment approximately doubled sildenafil AUC, while mild-to-moderate hepatic impairment increased AUC by about 85%.
Changes in CYP3A4-mediated metabolism can be even larger. In interaction studies, erythromycin increased sildenafil AUC by 182%, saquinavir increased it by 210%, and ritonavir produced approximately an 11-fold increase in AUC. These findings illustrate why AUC is sensitive to altered clearance and form part of the broader sildenafil PK variability framework.
| Source of Variation | Possible Effect on AUC Interpretation |
|---|---|
| Age | Older healthy volunteers showed higher total sildenafil exposure in labeling data. |
| Renal or hepatic impairment | Reduced clearance can substantially increase AUC. |
| CYP3A4 inhibition | Can markedly increase sildenafil exposure by reducing metabolic clearance. |
| Sampling duration | Affects how much exposure is directly observed. |
| Terminal extrapolation | Can influence estimates of total AUC beyond the final measured sample. |
Food illustrates why peak-related metrics and integrated exposure need to be interpreted separately. With conventional sildenafil tablets, a high-fat meal is associated with slower absorption, including a mean delay in Tmax of about 60 minutes and a mean reduction in Cmax of about 29%.
Those changes describe the rate and peak of systemic appearance rather than automatically establishing an equally large change in total AUC. A concentration-time curve can become flatter and shifted later while preserving much of its integrated area.
This makes food effects a useful example of why Cmax, Tmax and AUC should not be treated as interchangeable measurements. Quantitative food-effect interpretation belongs on the sildenafil food-effects page, which examines the relevant metrics together.
AUC is a central parameter in comparative pharmacokinetic studies because it provides a quantitative measure of the extent of systemic exposure generated by a pharmaceutical product. This makes it possible to compare how much circulating exposure follows administration of test and reference formulations under standardized conditions.
AUC is evaluated alongside peak-concentration measures such as Cmax rather than interpreted in isolation. Two formulations may need to be compared both for the extent of exposure represented by AUC and for relevant peak-exposure characteristics.
Bioequivalence analysis also depends on statistical comparison rather than simply comparing two raw AUC numbers. The regulatory and methodological interpretation of those comparisons is addressed separately on the sildenafil bioequivalence page.
| Parameter | Role in Product Comparison |
|---|---|
| AUC | Compares extent of systemic exposure. |
| Cmax | Compares peak concentration characteristics. |
| Tmax | Provides descriptive information about peak timing. |
AUC is a pharmacokinetic measure of systemic sildenafil exposure, not a direct measurement of pharmacological or clinical response. A larger AUC means that greater integrated circulating exposure occurred over the measured interval; it does not by itself establish how large a biological or clinical effect will be.
Exposure and response are connected through pharmacodynamics. Target interaction, concentration-effect relationships, signaling processes, active-metabolite contribution and individual biological factors all sit between measured plasma exposure and an observed clinical outcome.
This distinction is especially important when comparing populations or drug interactions that substantially increase AUC. A percentage increase in sildenafil AUC should not simply be converted into the same percentage increase in clinical effect. The exposure-effect relationship is treated on the sildenafil pharmacodynamics page.
| Domain | Representative Measure | Primary Question |
|---|---|---|
| Pharmacokinetics | AUC | How much systemic exposure occurs? |
| Pharmacodynamics | Biological response metric | What effect is associated with exposure? |
| Clinical observation | Observed outcome | What clinical response occurs under real conditions? |
AUC is most useful when interpreted as one component of the complete sildenafil pharmacokinetic profile. It summarizes integrated exposure, while Cmax describes the observed peak, Tmax describes peak timing, bioavailability contributes to systemic input and clearance helps determine how long exposure persists.
An AUC value alone does not reveal the exact shape of the concentration-time curve or identify why exposure changed. Similar AUC values can arise from profiles with different peaks and timing, while a higher AUC can result from greater systemic input, slower clearance or a combination of pharmacokinetic changes.
For sildenafil specifically, labeling demonstrates how useful AUC is as an exposure metric: pharmacokinetics are dose-proportional over the recommended range, while age, severe renal impairment, hepatic impairment and CYP3A4 inhibition can substantially increase systemic exposure. For the broader exposure framework, use the sildenafil exposure guide. The pharmacokinetics hub connects AUC with the complete ADME framework.
| Research Question | Most Relevant Metric or Concept |
|---|---|
| How much integrated systemic exposure occurred? | AUC |
| What was the highest observed concentration? | Cmax |
| When did the observed peak occur? | Tmax |
| What fraction reached systemic circulation? | Bioavailability |
| How efficiently was sildenafil removed? | Clearance |
Sildenafil AUC is the area under the plasma concentration-time curve and represents integrated systemic exposure across a defined time interval. It combines concentration and time rather than describing a single plasma measurement.
AUC is estimated from serial plasma concentration measurements by calculating the area between successive time points, commonly with a trapezoidal approach, and summing those areas across the selected interval.
AUC measures integrated exposure across time, while Cmax is the highest observed plasma concentration. Two sildenafil profiles can therefore have similar Cmax values but different AUC values, or similar AUC values with different peaks.
No. AUC is a measure of systemic exposure, while bioavailability describes the fraction of an administered dose that reaches systemic circulation unchanged. Bioavailability contributes to AUC, but clearance also influences the resulting exposure.
Sildenafil AUC can change when systemic input, metabolism or clearance changes. Labeling data show higher exposure with factors such as older age, severe renal impairment, hepatic impairment and CYP3A4 inhibition.
Not necessarily. Higher AUC means greater integrated systemic exposure, but clinical effect depends on pharmacodynamic processes, target interaction and other biological factors rather than AUC alone.